Edition:
India

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

12.40USD
21 Nov 2017
Change (% chg)

$0.51 (+4.29%)
Prev Close
$11.89
Open
$11.94
Day's High
$12.70
Day's Low
$11.80
Volume
197,793
Avg. Vol
222,818
52-wk High
$27.78
52-wk Low
$4.71

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $644.48
Shares Outstanding(Mil.): 42.23
Dividend: --
Yield (%): --

Financials

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

26 Oct 2017

BRIEF-Achaogen awarded up to $18 million contract by BARDA

* Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape

28 Sep 2017

BRIEF-Achaogen reports Q2 loss per share $0.78

* Achaogen reports second quarter 2017 financial results and provides corporate update

04 Aug 2017

BRIEF-Point72 Asset Management reports 5.5 pct passive stake in Achaogen

* Point72 Asset Management Lp reports 5.5 percent passive stake in Achaogen Inc as of july 25 - sec filing Source text - http://bit.ly/2vK96pV Further company coverage:

27 Jul 2017

BRIEF-Achaogen says board increased size from nine directors to ten directors

* Achaogen says on July 11, in connection with Karen Bernstein's appointment, board increased size from nine directors to ten directors - SEC filing Source: (http://bit.ly/2vifzY4) Further company coverage:

14 Jul 2017

BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate

* Initiates c-scape clinical development program with phase 1 study of orally-administered antibacterial candidate

01 Jun 2017

BRIEF-Achaogen announces pricing of public offering of common stock

* Achaogen announces pricing of public offering of common stock

25 May 2017

BRIEF-Achaogen offers up to 5 mln shares in public offering

* Achaogen announces proposed public offering of common stock

24 May 2017

Earnings vs. Estimates